Xifaxan Tablet
Product Images NDC 50090-2445

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Xifaxan (NDC 50090-2445). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure of rifaximin, the active ingredient in XIFAXAN 200 mg tablets. The structure shows the detailed molecular arrangement with various rings, oxygen, nitrogen atoms, and methyl groups as part of the compound.*

FDA Label Image

Figure 1 (Image 02)

A survival curve graph showing the proportion of patients without breakthrough hepatic encephalopathy (HE) over days post-randomization, comparing XIFAXAN tablets to placebo. The graph includes hazard ratio and confidence interval data, indicating a higher proportion without breakthrough HE for XIFAXAN compared to placebo over the observed period.*

FDA Label Image

Figure 2 (Image 03)

A line graph showing the proportion of patients without HE-related hospitalization over 168 days post-randomization comparing XIFAXAN and placebo. The graph includes labeled curves for XIFAXAN and placebo, with a hazard ratio and confidence interval provided, indicating statistical data for the comparison.*

FDA Label Image

Figure-3 (Image 04)

A clinical trial timeline diagram outlining multiple phases including Screening/Treatment 1, Treatment 2, Maintenance Phase 1, Treatment 3 Phase/DBR Treatment, Maintenance Phase 2, Treatment 4 Phase/SRT, and Follow-up. It shows study day 1, randomization 1:1, primary evaluation period (PEP), and primary efficacy analysis performed. Treatment intervals with 2-week Rifaximin (RFX), placebo (PBO), and follow-up periods are marked, spanning up to 18 weeks and beyond. A daily/weekly symptom diary is indicated throughout the trial period.*

FDA Label Image

Label Image (Lbl500902445)

The label for XIFAXAN 200 mg oral tablets from A-S Medication Solutions features the product name, dosage strength, and NDC number 50090-2445-0. It states each tablet contains 200 mg of rifaximin and includes storage instructions to keep the tablets at 68 to 77 degrees Fahrenheit. The label also contains a lot number and a 9-tablet count.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.